A SPECIAL
ANNOUNCEMENT FROM:  	  	[ACT Logo](http://www.appliedclinicaltrialsonline.com/) 	 
------


Dear Karina,


Here’s an eye opener: 


The number of FDA approved drugs per billion US dollars of R&D spend has halved every 9 years 

Success rates for new products in early development has fallen from 28% to 18%

Insufficient efficacy is the most frequent reason for early stage drug development failure


But fear not! [Exploratory Clinical Development World Europe](http://www.healthnetworkcommunications.com/conference/exploratory-clinical-development/?utm_campaign=8165+Exploratory%3a+ACT+email+2&utm_medium=email&utm_source=Eloqua&utm_source=ACT&utm_medium=op&utm_term=third-party&utm_content=emailblast&utm_campaign=op-act&elqTrackId=208B10EEC0A57D61D6330729D81DEDBF&elq=c3cb57e142cf4b54b059bd733fb65c04&elqaid=81366&elqat=1&elqCampaignId=) will help you plan and implement the right strategy to bridge the translational gap. It will provide you with the latest approaches and strategies to extrapolate results allowing you to take the best candidate forwards.


[Click here to see the topics to be discussed](http://www.healthnetworkcommunications.com/template/live/documents/8165/17343?utm_campaign=8165+Exploratory%3a+ACT+email+2&utm_medium=email&utm_source=Eloqua&utm_source=ACT&utm_medium=op&utm_term=third-party&utm_content=emailblast&utm_campaign=op-act&elqTrackId=89ED35779E0DB8BE4EE36A6AB7703AD5&elq=c3cb57e142cf4b54b059bd733fb65c04&elqaid=81366&elqat=1&elqCampaignId=) >>


Join 120+ participants and a leading panel of early development leaders address the most pressing challenges in Phase I/IIa trials


[BOOK NOW](https://secure.terrapinn.com/V5/step1.aspx?utm_campaign=8165+Exploratory%3a+ACT+email+2&utm_medium=email&utm_source=Eloqua&E=8165&p=1&_ga=1.80890133.362991328.1471013450&utm_source=ACT&utm_medium=op&utm_term=third-party&utm_content=emailblast&utm_campaign=op-act&elqTrackId=827D98AD01FDCCDAA9D2F208A487155C&elq=c3cb57e142cf4b54b059bd733fb65c04&elqaid=81366&elqat=1&elqCampaignId=) to save! The early bird price expires on 15th of September.


I look forward to meeting you in Berlin, 26th – 27th October. 


Kind Regards,


Zahid Tharia


Managing Director, Health Network Communications


ztharia@healthnetworkcommunications.com


+44(0) 207 092 1059


[Manage your Preferences](http://go.terrapinn.com/manage?utm_campaign=8535+BioData+USA:+M+Pletcher+interview&utm_medium=email&utm_source=Eloqua&elq=953497e10b864ead9a2ac91bcb9c8974&elqCampaignId=&elqaid=81640&elqat=1&elqTrackId=cd35120b570d4ead9f8c2bbfc2aaea44)

This email was sent to: [ kkusova@healthnetworkcommunications.com ](mailto:kkusova@healthnetworkcommunications.com)

To leave our mailing list, simply [click here](http://go.terrapinn.com/global-unsubscribe?utm_campaign=8535+BioData+USA%3a+M+Pletcher+interview&utm_medium=email&utm_source=Eloqua&elq=953497e10b864ead9a2ac91bcb9c8974&elqCampaignId=&elqaid=81640&elqat=1&elqTrackId=2a604543e77d4d899c793c80332e535c)

Terrapinn respects your [ privacy ](http://www.terrapinn.com/privacy?utm_campaign=8535+BioData+USA%3a+M+Pletcher+interview&utm_medium=email&utm_source=Eloqua&elq=953497e10b864ead9a2ac91bcb9c8974&elqCampaignId=&elqaid=81640&elqat=1&elqTrackId=7734d6121a09499c9d19977636f9f119)

Health Network Communications Ltd , Wren House, 43 Hatton Garden, LONDON, EC1N 8EL